Lantheus (NASDAQ:LNTH) Given New $99.00 Price Target at B. Riley

Lantheus (NASDAQ:LNTH) had its target price boosted by B. Riley from $95.00 to $99.00 in a research note issued to investors on Thursday morning, Benzinga reports. B. Riley currently has a buy rating on the medical equipment provider’s stock.

Several other brokerages have also commented on LNTH. Truist Financial reissued a buy rating and set a $82.00 price objective (up previously from $80.00) on shares of Lantheus in a research report on Monday, February 26th. JMP Securities reissued a market outperform rating and set a $100.00 price target on shares of Lantheus in a research report on Friday, February 23rd. Finally, StockNews.com upgraded shares of Lantheus from a hold rating to a buy rating in a report on Saturday, January 13th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of Moderate Buy and a consensus price target of $104.71.

Lantheus Price Performance

LNTH stock opened at $62.33 on Thursday. The company has a debt-to-equity ratio of 0.69, a current ratio of 5.80 and a quick ratio of 5.45. Lantheus has a 1 year low of $50.20 and a 1 year high of $100.85. The firm has a 50-day moving average of $60.66 and a 200 day moving average of $62.99. The company has a market cap of $4.27 billion, a P/E ratio of 13.43 and a beta of 0.53.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share for the quarter, topping analysts’ consensus estimates of $1.33 by $0.26. The firm had revenue of $354.00 million for the quarter, compared to the consensus estimate of $350.44 million. Lantheus had a return on equity of 63.16% and a net margin of 25.20%. On average, sell-side analysts forecast that Lantheus will post 5.72 EPS for the current year.

Insider Buying and Selling

In other Lantheus news, Director Mary Anne Heino sold 93,863 shares of the firm’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the completion of the sale, the director now directly owns 251,643 shares in the company, valued at approximately $16,434,804.33. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Lantheus news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The stock was purchased at an average price of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the purchase, the insider now directly owns 116,773,394 shares of the company’s stock, valued at $110,934,724.30. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Mary Anne Heino sold 93,863 shares of the stock in a transaction on Monday, March 4th. The shares were sold at an average price of $65.31, for a total value of $6,130,192.53. Following the sale, the director now directly owns 251,643 shares in the company, valued at $16,434,804.33. The disclosure for this sale can be found here. Insiders have sold a total of 94,545 shares of company stock worth $6,169,936 in the last quarter. Corporate insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Lantheus

A number of hedge funds have recently bought and sold shares of LNTH. State of Michigan Retirement System grew its stake in shares of Lantheus by 2.4% in the first quarter. State of Michigan Retirement System now owns 16,800 shares of the medical equipment provider’s stock worth $1,046,000 after acquiring an additional 400 shares during the period. Allspring Global Investments Holdings LLC raised its stake in Lantheus by 25.9% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 88,046 shares of the medical equipment provider’s stock valued at $5,480,000 after buying an additional 18,119 shares during the last quarter. Oliver Luxxe Assets LLC bought a new position in shares of Lantheus during the 1st quarter valued at $547,000. City State Bank boosted its stake in shares of Lantheus by 44.6% in the 1st quarter. City State Bank now owns 1,945 shares of the medical equipment provider’s stock worth $121,000 after buying an additional 600 shares during the last quarter. Finally, Silverberg Bernstein Capital Management LLC boosted its stake in shares of Lantheus by 1.8% in the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 22,743 shares of the medical equipment provider’s stock worth $1,416,000 after buying an additional 400 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.